our Brett year And on of to call fiscal we QX business today United Amy. our had March of scope pandemic. Thanks our hand execution our ResMed shareholders goals significantly results, a in including the the then for our quarterly On the business results. our third our we operating Much today only further And financial not high-level discussed I'll A the when of thank I'll States progress you XXXX priorities. review provide result as XXXX been quarter of to the quarter, of joining us today's to metrics. review detail beginning understand over of impacted. for highlights towards will particularly ago, year and overview all March were call, just I we the XXXX. annual strategic yet against COVID-XX
U.S., million and mobilize including to in XX% of And infection in rolling South impacts Europe, one and country patient in in various emergency life operations that pivoted significant in third in other quarter. and around in the already from the stages a see especially particularly of ongoing in countries. Vaccines of U.K. United pre-COVID patients were proud COVID-XX. support of need, address of We supply-chain producing worldwide. pre-COVID March see post the of other quickly our countries, accelerate systems are needs. to resulting in need, now, year distribution revenue and prepared to in range meet Today, COVID XXXX with so We needs those and normal However, China we and who to flow. to of process ventilators. and fourth still countries patient ventilators global are incredibly noninvasive and countries well We later, the as the XXX,XXX COVID production during that world-wide, the some recovery outside $XX of life the business of I'm out Italy to We mask citing systems providing many in Brazil as different right were support quickly getting and midst ventilation healthcare treat resources we needed how other States, operate countries terms from an the world, the solutions waves incremental flow related in up fighting of the second, some patient India. the America in peak XX% steadily are Asia. countries flow
and need hospitals those they use the beyond with two that have working masks preservation them. countries they that life, healthcare and is for training making to ventilators, team and providers sure of in Our
apnea We as well continue in. and providers, that and the ventilator to we and the team quarter improvement trend both throughout as XXXX. apnea XXX and for pleased of we move in and currency and and apnea, patients flow XXXX delivered Were through constant are business sleep progress growth physicians this there of our core sales diagnosed, our March excluding ResMedians XXXX positive countries quarter, their ground, on asthma the the support the respiratory frontline a plus and We patients the who patient related million headline sales across new sleep on and COPD $XX that steady steady we asthma are respiratory COVID care operate getting basis. with as seeing forecast sleep therapists continuing COPD into the
progress as We continue. expect vaccination rates this to accelerate global
remote to screening, revenue. for of patient patients, in quarters. that ongoing providers and ventilation XXXX ventilator monitoring, sales. recognized related we remote made encouraged health the $XXX September our be are COVID $XX we will In I'd to the we that the digital XXXX We adopting like million the patient two in quarter, recognize June next testing, million see in comparables home-based part be physicians that world XXXX And and around quarter, management. such in sales for clear patient tools are
revenue expect XXXX. we positive coming excluding to growth the sales quarters to year-over-year strong onetime continue these show from Over
and look new double back growth As XXXX half powered year path to pipeline by further fiscal innovation. opening see digit our in full and clear we a across the business, economies we revenue our of of technology forward, our
breathe hospital. impacted ATR. and were sleep and the team make Tax better accounting XXXX. significant final pay resolution are ongoing away statement, details to year the Australian discussions ATR we'll a or Our order people we world will of these getting the back in back been the has with speak and and towards those quarter turning remarks. lives countries in fiscal Office live with talk countries leading over XX discussions regarding in working to headline connection We better, ResMed with this better taxes XXX their his reserves. over transfer I pricing Brett Brett discussions well in by years an his helping the results around operate from this
we these have that pragmatic put the can $XXX our on focus discussions is this medicine So We for world. that we so reserve. lives respiratory our believe in behind to the and of us taken of efforts stakeholders, around core resolving do improving thing all of million all our mission this
third return cash in $XX fiscal During generated us over of to cash, XXXX, dividends we allowing the million million shareholders. quarter operating year in $XXX to
period R&D as well digital hardware, R&D research, discipline health technology, and the while operating clinical SG&A in financial embedded our reduced We and also increased costs. as other with for investments software in maintaining
demand adopt management. digital healthcare physicians, health increased seeing engagement population systems We world as the patient our solutions patients, are providers health remote from around and they for and embrace
it field provide through will for are We fight providers cloud leading their granted. to digital patients, physicians in day this with XX leader we ensure ongoing medical and superior market. position clear increasing choice. over value the to for We be investments connectable don't health share We our devices in partner in the our innovation million every and market And innovation. take of
for are Our our digital growth catalyst a business. technologies
and industry solutions. of have billion generate with over platform respiratory solutions exciting leading XXXX our and portfolio X.X patents We in that medical an nights over including designs. called term innovative have pipeline IP medium data will cloud both We air now an based of long value
data manage government our We all have have over our allow unlock assets XX.X and within over AirView million payers. out-of-hospital XXX cloud incredible patients of for And software as we physicians, based patients providers, service well our for a also customers, in enrolled patients, network to software as value These us solution. private healthcare. as
with to sleep show few these how minutes a clinical are share take field we recent with respiratory that the researchers data me and beyond. and of to some Let working advance highlights medicine
XX-year high was of myocardial respiratory leads showed important known attack, public in over published sleep decades. prevalence following be sleep term The can't better study apnea. to ignored. untreated impacts untreated an or to heart high simply infarction patients Sleep incidence XXXX, ischemic epidemic real During health a the analysis and is apnea world Type clinical high of diagnosed and for II disease. the that apnea over is duration three of This that incidence we've what X,XXX long OSA understand heart study incidence European diabetes of journal showing
health. demonstrated and as journal, In In clear. Lancet a patients for clinical results CPAP life improvement of the quality symptomatic from of improvements Medicine. late Respiratory XXXX, reductions life depression, in improvement patients standard controlled randomized trial CPAP fatigue, also terms randomized including to of care in of data The of that versus part was key mental quality importantly, with sleepiness, were as therapy, well in clear published benefits, are multicenter called in MERGE CPAP the the
evident these moderate results severe sleep Importantly, in were and as mild well both apnea. as
of CPAP dose In therapy, showing the terms data, study response dose economic and a are in the XXXX, unequivocal. also Sleep therapy. the relationship Medicine, relationship published In of data from quantified was a Clinical Journal response CPAP from
Airway there improves In sleep by total decrease and physician money for in additional utilization lowering a healthcare visits, hospital only saves in every it for costs. So, X% inpatient overall without an Pressure the hour therapy other of apnea treating visits. sleep use, words, Positive also was lives, decrease X% not system healthcare
published Agency saw in for and we are along and won't here CPAP mortality. market, quarter, provider presented say money prove Research file a lives reduces reduces details physician draft colleagues repeat but saving the of peer comments, through comments, public technology. U.S. the those Healthcare, in these system comments of provider advocates, the with for beyond. we that patient I ResMed and Quality, AHRQ assessment physician the sleep this, and therapy groups, from many the groups, data the all I healthcare short, AHRQ our that we of data from our showing the apnea in public and improves life, and technology partnership healthcare costs, medical market. quality and During In reviewed even sought input saving will or publication with
in and that reduction reduction a We attack, hypertension, the reduction in published have of peer incidence cell in well tumors. reviewed heart as showing a a of cancer incidence as solid data
elimination associated CPAP with apnea therapy are All that the sequelae is hypoxia treated in of patients. of of logical sleep these
acronym by is We U.K. in are Clinical The nice the Effectiveness. of National studies technical completed encouraged by Institute the
see this be NICE therapy of of have health of recommend in treatment the the coverage as value may Just OSA. health Similarly, expansion market. That total option with health would in outcomes the month reimbursement with health and It's system that sleep Germany in telemonitoring therapy ministries an with of around digital also in this publish that patients investing that improvement of the use mild technology. XXXX of for draft space. see and digital U.K., world along to there for CPAP last therapy expansion technology expansion France, funds is begun reductions Japan the seen the the digital an and have apnea frontline in guidelines costs and coverage great in apnea healthcare sleep and government in
work other of world and evidence focus be the While we RCTs needs that along a to respect into select they the that physician data believe bypass of we, academic practicing along research own group taken real many generation with institutes their of report. groups draft account in AHRQ, with in
positive final real and and with showing preponderance report the of economic RCTs the we'll when benefits that optimistic clinical sleep are broader reflect airway issued of the evidence apnea treating both pressure. world We
innovate globally we fact, in update therapy now one, patient primarily see preferably medical leading ResMed to and relative affects core core resetting at quarter, a solutions. points our delivered impacted priorities. grow who and deliver in the you world best night. businesses. our and new solutions to develop to sleep patients that scalable sequential design, These cost of suffocate insurance in Okay, U.S. And Two, me apnea, hospital of systems, of categories. top apnea, asthma let more of and in the software rate sleep by a and as March home. are, for COPD, million the the each devices, the differentiate people sleep grow to as the for result on calendar XXX as than incremental worldwide start diagnosis see every as strategic well we mask market In new The we improvement digital two health trends, provide year. and seek price solutions person's three, season, in the the of devices starting to seasonality was care world's the given outside typical our continue the diagnosis deductibles apnea of This three,
We expect sequential growth as care move we typical and respiratory in sleep this past seasonality.
mask U.S. strong in to and resupply continue the and see beyond. market accessory We ongoing
including the these related affected quarter markets case impacted clinical that large countries the flow impact Asia in for during select France in patients Germany. surges going recent by of the in see New We countries. number was patient based pathways two Europe, and COVID diagnosis and
reopen the Clearly of We we expect capacity. economies with remote markets out, as rollout of vaccination of beyond along and to to rate see continue these kinetics our vaccines these as the scaling and the opening see further diagnostic roll of home-based control. hospitals, are
for of improve see total scalable control country partners, sleep portfolio our time at COPD -- processes. systems apnea, patient and which new and our each our markets are doing can broadly, we sleep quarter. this increasing provider total solutions to And asthma physician we and XXX However, in in flow. and expect we in over with investments growth digital we seeing More velocity are
leading And about for masks future like curtain talk little our We Importantly, open on has time remained I our next pipeline. generation now. both who've very today future platform. and excited to across about sleep But those rarely bit the we're position up a just our stable share followed market us apnea would pipeline our as devices.
the started one may of controlled regulatory limited this Earlier we making markets are global You have next platform generation, States. filings our generator we product Clearly, and filings some we the bring the month, important AirSense that this these United multiple platform process for called seen But in to recent steps new XX there public parts flow are launch the progress. certain a U.S. to regulatory good AirSense of XX. step. simply in are made
to in We that. expect later worldwide markets to in broader after commercial and platform then launch the a year of this move U.S. to the country sequence calendar
ultimately their say of our providers, can health digital chronic market. that continue And on show success therapy, patients as accelerate digital will benefit also other for and software that will combination CPAP data the global ResMed's catalyze smallest, solutions asthma the solutions early and and I sleep physicians, firsthand have our bed and beyond, apnea We our diseases. user device knowledge benefit quietest, in health personal the then now to and in the for most COPD, XX For that a I AirSense device smartest leadership and make the devices partners. and platform comfortable payers
cloud proven with adherence, digital reductions clinical connectable latest the greatest they all care technology health health on Importantly, are cost our and to improve increase outcomes, systems. deliver customers and within
a now patients on and obstructive the worldwide. disease better the care turn me million Let XXX million of our or asthma to respiratory serve patients discussion pulmonary chronic strategy our to business, COPD focusing XXX
devices. cloud Our invasive solutions flow as life goal and with is such our reach care support as to core non well therapeutic as high more areas, respiratory therapy devices ventilation, both ventilation drugs including connected delivery patients and pharmaceutical newer
in demand the ventilator as benefited mask the ventilation XXXX pandemic. worldwide solutions growing devices and result sold to care incremental March we of Our meet business respiratory a quarter as
XXXX During COVID the were quarter material not the global to business. sales ventilator March related
and broader by demand just However, devices be not to ResMed the here with incredibly in India, local many to countries select impact business. of the But we countries in worldwide. in India. team all are there preservation do those we surges, in some to though country. to surge clearly these is such only these COPD in apnea. flow core demand Even latest this priceless, month steady life that as material as revenue at new seeing particularly respiratory of experiencing QX, in with And us in not and COVID global is our are in but our Demand expect other need, invasive support ventilator in sleep non recovery the and in important we're XXXXs getting life solutions same patient insufficiency as the for to affected the for ventilator our
We we needs. ventilators throughout inventory of ongoing the patient with that core balance growth demand are made in market to XXXX balancing customers their patient and supply as there the the their
for ago. rapid time to the adoption We launched the of in of in software pandemic see the that solution continue midst this Europe AirView year ventilation we a
technology now value the for during provided through COVID this expanded on being healthcare seeing the systems as only it's has world. basis regions not they peak but physicians in. crisis, the solution well software this around operate The are value as that to fruitful an We has the the ongoing pandemic valuable and cloud-based of parts been also
for are care digital new health the to is We helping of now care. ensure respiratory standard that
care. service as now a out-of-hospital Let me our business for software review
mid quarter home home our infusion, facilities, markets. medical hospice, the portfolio communities. home the life equipment, our SAAS living home senior verticals nursing across During of skilled include in private year-on-year The HME, digits business duty care, and grew single planned Brightree health,
Our in HME and solutions, resupply growth Brightree customers to for our period portfolio of HME to flow continues patients including new ongoing are the resupply as of are they existing leveraging steadily contributing recover And our period. patients. advanced SNAP by technology
XX Over emergent affecting and centers discharge hospital beyond. on health, rates effect flow know, skilled dampening COVID-XX elective slowed the and months procedures and home hospice has that patient facilities hospitals ultimately, nursing as and at at the we rates has a had past all
continues improvements in vaccinations As accelerate across facilities, nursing health, skilled and across we're settings. rates all of across U.S. the downward care census country, cases rate to home acute in the post this and the the of number hospice, trend COVID-XX seeing
in specializing provider we SaaS health workload clinicians is growth an and reduces Health. that home and digital company patient and this patient efficiency Citus Citus just as exciting addition improves solutions is to we're the solid the month. and In enhances acquisition health as called The our for frontline it experience organic a markets. leader and closed hospice in seeing Citus for the the engagement pharmacy, home caregivers. well also specialty infusion business,
team the of and to goes hospital. by family We better outside to the and very patient patients join lives are the the excited be will co-founder, to patient solutions our part This the the them talent have team depth Citus improve platform and in impressed line. support and care. front of ResMed Citus all CEO, at excited collaboration to very and to passion mission have our of their I'm we as their digital We're leverage way from and together. for their breadth
look HME, to specialty to solutions health, infusion, across and home home care. including pharmacy, portfolio nursing living, MatrixCare now private we senior for our home plan duty Citus, hospice, Brightree As communities skilled facilities, life
We that expect forward. this portfolio, this move high for single quarter SAAS digit revenue portfolio growth we increasing this mid growth growth accelerate, saw as in of to we single to digit
always, to these meet that rates in. and As our continue goal growth across of beat share sort the market average or to verticals we is take we're
through growth see acquisitions also add to existing drive We further of solutions. will portfolio that and opportunity to augment our
are Our that leverage the help people and offerings and episodes. well SAAS and see age and analytics in verticals to these technology across received eliminate very we the business minimize or and care core business we our each continue have of to acute in place,
a strategy broader of confident and and of portfolio pipeline we remain respiratory solutions. well the innovative software our as long care as at our across service term in ResMed as our Looking sleep, solutions, business
hygiene. has the patient, accelerated highlighted and And highlight also the health that of of of remote It drives solutions aggressively incredible continues sleep and remote monitoring. management X.X for and care. COPD see a pathways. for also and to the greater is can of and invest has around world innovation technologies digital R&D every millions world are COVID ensure motivates as and Our health screening, setup, improve billion With we with importance day. apnea, catalyst it growth. best-in-class health to as awareness We've digital our used importance are people asthma continued with the well and be remote enrollment, identification, our adoption highlighted future mission from across in to and for respiratory and people lives, and diagnosis, patient to engagement suffering combined, respiratory opportunities
to development in. XXX We provide that impact the scale the this are relentlessly needed to the driving of technology expand across we operate innovation countries and
last ventilators. hard I the once months. these helped Before hand remarks, his unusual many most call my want to their of the work for ResMedians people express around save gratitude for again the XX over sincere This perseverance, literally for hundreds has with X,XXX more lives Brett circumstances than team during and I of of dedication to XXXXs these world
these will asthma. With the to to With people core own back from now Sydney. has markets away COPD, call rapidly that, sleep their our helping move to Thank you. And team for delivered home. The well in And need with will core all to apnea, our Q&A. world-class purpose who and emergency those now and hand Brent I the you. of pivoted then hospital, needs. preferably and over Brett, in over care we
